Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$547M in Q4 2025 → $53.6M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Caris Life Sciences Inc | 100.0% | Trimmed 84% | 1,750,615 | $53.6M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2026 · filed November 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Caris Life Sciences Inc | Trimmed | −9,506,000 | −$291M | 100.0% |
quarter ended June 30, 2026 · filed August 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Caris Life Sciences Inc | Trimmed | −7,000,000 | −$125M | 100.0% |
quarter ended March 31, 2026 · filed May 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Caris Life Sciences Inc | Trimmed | −2,000,000 | −$35.8M | 100.0% |
Loading...